Saturday, October 3, 2026

USD/EUR Over 1% Down In The Last 5 Sessions

ViaNews Editorial Team

December 14, 2023

USD/EUR Over 1% Down In The Last 5 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.09% for the last 5 sessions. At 12:07 EST on Thursday, 14 December, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 3.586% up from its 52-week low and 4.002% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.08%, a negative 0.05%, and a positive 0.31%, respectively.

USD/EUR's highest amplitude of average volatility was 0.20% (last week), 0.36% (last month), and 0.31% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Thursday, 14 December, "Apart from this, the post-FOMC selling around the Greenback, which remains unabated, drags the USD/JPY pair to the 141.15 region in the last hour. ", "Some follow-through selling below the 141.00 mark has the potential to drag the USD/JPY pair further towards the 140.40 intermediate support en route to the 140.00 psychological mark. "
  • According to FXStreet on Tuesday, 12 December, "With oscillators on the daily chart still holding deep in the negative territory, some follow-through selling could make the USD/JPY pair vulnerable to accelerate the slide further towards the 145.00 psychological mark en route to the 38.2% Fibo. ", "The Japanese Yen (JPY) extends its steady intraday appreciating move against the US Dollar (USD) and drags the USD/JPY pair to a fresh daily low, below mid-145.00s heading into the European session on Tuesday. "
  • Usd/jpy price analysis: set to extend losses as bears take control. According to FXStreet on Tuesday, 12 December, "On the upside, the USD/JPY must reclaim the Senkou Span A at 145.86, ahead of the confluence of the Kijun-Sen and the Senkou Span B at 146.75.", "The USD/JPY is neutral to downward based after diving below key support levels, like the Ichimoku Cloud. "
  • Usd/jpy grinds into the middle just above 145.00 ahead of the year’s final fed rate call. According to FXStreet on Wednesday, 13 December, "The USD/JPY is seeing a rough box forming on the intraday charts as the technicals take a step down against major fundamental events, leaving the pair to cycle around 145.50 in the midweek market session.", "The USD/JPY is caught in the middling recovery range of last week's plunge into 141.60, with the bullish rebound getting capped off by resistance from the 200-hour Simple Moving Average (SMA) descending into the 146.00 handle, and near-term chart action is seeing technical support from the 145.00 handle."
  • Usd/jpy analysis: eyes turn cautiously to the federal reserve's decisions - 13 December 2023. According to DailyForex on Wednesday, 13 December, "Since the start of trading this week, the price of the USD/JPY has been trying to rebound higher. ", "Thus, that's indicating that the USD/JPY may be among the most volatile pairs after the Fed announced its decision."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com